Pfizer licenses small molecule drug delivery technology from Serina
Pharmaceutical Technology
NOVEMBER 20, 2023
Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
NOVEMBER 20, 2023
Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.
Roots Analysis
FEBRUARY 26, 2024
Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. Our Social Media Platform Web: [link] LinkedIn: [link] Twitter: [link] The post Subcutaneous Medications and Drug Delivery Systems appeared first on Blog.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Reporter
OCTOBER 31, 2023
The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.
Outsourcing Pharma
JANUARY 12, 2023
Biogen partners with Alcyone to gain access to ThecaFlex, which is able to deliver therapies into the intrathecal space.
Bio Pharma Dive
APRIL 13, 2022
Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.
BioTech 365
DECEMBER 1, 2021
Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery FOXBOROUGH, Mass.–(BUSINESS Suono Bio, Inc.
BioTech 365
JUNE 22, 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to … Continue reading →
BioTech 365
AUGUST 19, 2021
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures (..)
Fierce Pharma
APRIL 17, 2024
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday.
Pharmaceutical Technology
APRIL 17, 2023
US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals is developing STS101, a unique nasal powder formulation of the anti-migraine drug dihydroergotamine mesylate, for the treatment of acute migraine. In March 2023, Satsuma submitted a new drug application for STS101 to the US Food and Drug Administration (FDA).
Delveinsight
MARCH 2, 2021
HitGen & UPPTHERA Collaborate for Drug Delivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Junshi & AstraZeneca To Commercialize Toripalimab in China.
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 Juyou Bio-Technology Co.,
Roots Analysis
FEBRUARY 22, 2022
Further, in order to improve the quality of life in these patients, companies have developed novel devices capable of delivering a variety of formulations of different drugs / therapies, in an efficient and relatively simple manner. Autoinjector As Emerging Drug Delivery Device.
Drug Discovery World
MARCH 3, 2023
Under the terms of the agreement SiSaf has an exclusive option to acquire a worldwide license to a patent by the University. SiSaf will develop miRNA Bio-Courier formulations that will be tested in pancreatic cancer models in Professor Aigner’s laboratory.
pharmaphorum
JANUARY 3, 2023
The change at the top comes as ReNeuron is in the throes of a pivot in its business after years of stuttering progress with stem cell programmes and a perennial shortage of operating cash, with the company announcing in July it would concentrate efforts on a proprietary exosome drug delivery platform.
Drug Discovery World
JANUARY 16, 2024
The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. The post Clinical trial will test novel inhaled TB vaccine appeared first on Drug Discovery World (DDW).
pharmaphorum
MARCH 16, 2022
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now. Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1
The Pharma Data
OCTOBER 20, 2020
We look forward to successful commercialization and licensing of TLC’s programs across the globe under Mr. Bliss’s leadership, as well as to creating benefit and bringing value for all of TLC’s stakeholders.”. Earlier in his career, he ran business-development functions at Amgen and Baxter.
The Pharma Data
JUNE 7, 2023
LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
Drug Discovery World
FEBRUARY 16, 2023
The company’s protein nanoparticle (PNP) genetic medicine delivery platform is based on the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo.
Druggist
NOVEMBER 19, 2020
Formoterol, which belongs to a group of drugs called long-acting beta2-agonist ( LABA ). pMDI inhalers are composed of an aluminium canister with a propellant (spray) and an active drug inside, metering valve, and actuator. . Initial license for Fostair included only maintenance therapy in adults over 18 years of age.
The Pharma Data
DECEMBER 20, 2020
With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.
The Pharma Data
DECEMBER 28, 2020
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife Pharma Inc. No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release.
The Pharma Data
DECEMBER 14, 2020
While the medicalization of psychedelics is evolving and gaining momentum at an extraordinary pace, such therapeutics still face regulatory hurdles in the areas of manufacturing, formulating, and ultimately dispensing or the rescheduling of Schedule I drugs to patients. BetterLife Pharma Inc.
The Pharma Data
JANUARY 25, 2021
Further to the update outlined in the Company’s results for the year ended 31 December 2019, Secura Bio, Inc. (“Secura Bio”), the licensor of panobinostat, the API component of MTX110, has twice declined an invitation to withdraw its purported termination of the license.
The Pharma Data
SEPTEMBER 2, 2021
GLY certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura. MF is exclusively licensed to Novartis from a subsidiary of Merck & Co., Mometasone furoate is exclusively licensed to Novartis from a subsidiary of Merck & Co., g) formulations.
The Pharma Data
JANUARY 27, 2021
FDA Investigational New Drug (“IND”)-enabling pharmacology studies. About Eurofins Discovery: Eurofins Discovery, a business operating under the Eurofins BioPharma Services division, has supported drug discovery research for over 40 years. About BetterLife Pharma: BetterLife Pharma Inc. For more information, please visit: [link].
The Pharma Data
JANUARY 18, 2021
According to Health Canada, “the information currently available at the Controlled Substances Directorate, 2-bromo-LSD is NOT CONTROLLED under the Schedules to the Controlled Drugs and Substances Act.”. BetterLife Pharma Inc.
The Pharma Data
JUNE 26, 2021
Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S.
The Pharma Data
NOVEMBER 25, 2020
In addition to its pharmaceutical, medical device, advanced diagnostics, medical supply, medical technologies, neurosciences, and health and human service divisions, the Company has global exclusivity to license the patented and patent-pending TABMELT ® sublingual drug-delivery system for the pharmaceutical use of therapeutic compounds.
BioSpace
NOVEMBER 17, 2022
Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.
The Pharma Data
OCTOBER 27, 2020
DermSafe is listed by Health Canada under its approved products “ Disinfectants and hand sanitizers accepted under COVID-19 interim measure ” and has two Drug Identification Numbers (DIN) for personal use and personal commercial use. Statements have not been evaluated by Health Canada.
Pharmaceutical Technology
FEBRUARY 15, 2023
“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.
The Pharma Data
JANUARY 3, 2021
The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.
pharmaphorum
JANUARY 12, 2021
ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. The post Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech appeared first on.
Drug Discovery World
NOVEMBER 9, 2023
Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Ioanna Stamati, PhD, Team Leader, Bioconjugation, Antikor Biopharma, on: ‘Antibody fragment drug-conjugates (FDCs): Analysing novel formats with high DAR’.
The Pharma Data
DECEMBER 17, 2020
With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec.
The Pharma Data
MAY 15, 2023
Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). 1,2 Vabysmo’s safety profile was consistent with previous trials. Review by other regulatory authorities is ongoing.
Druggist
OCTOBER 21, 2020
Terbinafine is recommended as the first-line oral antifungal drug. Topical products for toenail fungus treatment are recommended as the first option due to a better safety profile as compared to treatment with oral antifungal drugs. Additionally, oral antifungal tablets are not licensed for use in children.
The Pharma Data
JANUARY 15, 2021
Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1]
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content